Compare CNMD & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNMD | ALVO |
|---|---|---|
| Founded | 1970 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | 1460 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 985.5M | 1.0B |
| IPO Year | 1995 | N/A |
| Metric | CNMD | ALVO |
|---|---|---|
| Price | $49.72 | $3.74 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $46.25 | $8.00 |
| AVG Volume (30 Days) | 734.0K | ★ 789.9K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.22 | N/A |
| Revenue | ★ $1,374,724,000.00 | N/A |
| Revenue This Year | $0.82 | $13.28 |
| Revenue Next Year | $5.48 | $18.63 |
| P/E Ratio | $40.26 | ★ $18.20 |
| Revenue Growth | ★ 5.18 | N/A |
| 52 Week Low | $31.44 | $2.94 |
| 52 Week High | $56.64 | $9.25 |
| Indicator | CNMD | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 64.63 | 56.25 |
| Support Level | $40.14 | $3.10 |
| Resistance Level | $53.66 | $4.04 |
| Average True Range (ATR) | 2.10 | 0.23 |
| MACD | 0.25 | 0.05 |
| Stochastic Oscillator | 63.63 | 68.52 |
Conmed Corp is a medical technology company that provides devices and equipment for surgical procedures. The company's products are used by surgeons and other healthcare professionals across specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. Geographically, the company operates in the United States, Europe, the Middle East & Africa, Asia Pacific, and the Americas, excluding the United States. The majority of revenue is generated from the United States.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.